after four weeks of treatment , those patients treated with taa showed highly significant ( p less than 0.001 ) improvement from baseline in pulmonary function tests ( fev1 , fvc , and fef25-75 % ) and in asthmatic symptoms , whereas no significant improvement was observed in those patients who received placebo aerosol .
C0040866
taa
C0004096
asthmatic